|
Basic Characteristics of Mutations
|
|
Mutation Site
|
M204I |
|
Mutation Site Sentence
|
Mutations conferring resistance to lamivudine and telbivudine were most common (rtL180M and rtM204I/V) (74.3% of total mutant samples). |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RT |
|
Standardized Encoding Gene
|
P
|
|
Genotype/Subtype
|
G;D;H;B;F;E;C;A |
|
Viral Reference
|
AY090460;AF160501;X75658;X75657;V01460;X01587;D00329;X02763
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Hepatitis B Virus Infection
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
Lamivudine(LAM);Telbivudine(LDT) |
|
Location
|
America |
|
Literature Information
|
|
PMID
|
21723325
|
|
Title
|
Development and validation of a hepatitis B virus DNA sequencing assay for assessment of antiviral resistance, viral genotype and surface antigen mutation status
|
|
Author
|
Mallory MA,Page SR,Hillyard DR
|
|
Journal
|
Journal of virological methods
|
|
Journal Info
|
2011 Oct;177(1):31-7
|
|
Abstract
|
The objective of this study was to develop a DNA sequencing assay that examines sensitively and reliably all conserved domains of the reverse transcriptase-encoding region of the HBV genome for antiviral resistance-associated mutations while simultaneously producing ample information for precise genotyping and determination of HBsAg mutation. This assay was used to examine 1000 de-identified HBV DNA positive samples with known viral loads from a broad-based, unselected patient population from across the United States. Of these, 946 were assayed successfully. Antiviral resistance-associated mutations were identified in 104 samples. The escape mutation sG145R in the surface antigen was identified in 0.8% of patient samples. Infections with genotypes A, B, C, D, E, F, G and H were observed in 36.6%, 19.6%, 21.7%, 13.5%, 3.6%, 0.7%, 2.2%, and 0.5% of patient samples respectively. Fifteen samples (1.6%) appeared to harbor infections with multiple genotypes as shown by the presence of double peaks throughout sequence electropherograms. The limit of detection of this assay was approximately 150IU/mL.
|
|
Sequence Data
|
-
|